Adjuvant Therapy With Pegylated Interferon Alfa-2b-Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cacncer Melanoma Group (CROSBI ID 562223)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Sales F, Gore M, MacKie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A
engleski
Adjuvant Therapy With Pegylated Interferon Alfa-2b-Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cacncer Melanoma Group
Adjuvant Therapy With Pegylated Interferon Alfa-2b-Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cacncer Melanoma Group
interferon Alfa-2b; melanoma
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
2916-2923.
2009.
objavljeno
Podaci o matičnoj publikaciji
J Clin Oncol
N, N
Narodne novine
0-000-00000-0
0000-0000
Podaci o skupu
J Clin Oncol
poster
01.01.2009-01.01.2009
N, N
